Guardion® Announces Development of Unique Immuno-Supportive Complex Targeting Upper Respiratory Tract Infections
February 06 2020 - 7:00AM
Guardion Health Sciences, Inc. (“Guardion” or the “Company”)
(Nasdaq: GHSI) announced the development of a unique proprietary
formulation to provide immuno-support and anti-inflammatory
benefits targeting the upper respiratory tract. The Company’s
efforts are being spearheaded by its recently acquired NutriGuard
business line. NutriGuard formulates high-quality,
scientifically-credible, condition-specific nutraceuticals designed
to supplement consumers’ diets and assist in the prevention and
management of an array of diseases and conditions.
This proprietary new product, to be
preliminarily labeled acuMMUNE (trademark registration pending),
was designed by Guardion’s internal product and technology design
team, and is the first product to be introduced by Guardion under
the NutriGuard label. The acuMMUNE formulation was designed with
the objective of supporting effective immune function – including,
in particular, interferon-mediated anti-viral mechanisms – while
also mitigating the excessive lung inflammation that can lead to
the harsh symptoms and even death caused by severe lung infections
associated with certain viral infections.
acuMMUNE will initially be offered in a capsule
form and will be available in the United States through the
Company’s web-site (www.guardionhealth.com and www.nutriguard.com).
The Company is currently in the process of arranging for the
manufacture and packaging of acuMMUNE at contract facilities in the
United States and expects that this product will be available for
sale beginning in approximately April 2020. The Company anticipates
that acuMMUNE will also be available for export to various
international markets shortly thereafter.
Recently, the coronavirus (2019-nCoV) has
developed into a worldwide epidemic, with over 20,000 cases
confirmed in China since it was first detected in December 2019,
and is a growing risk to global economies. The World Health
Organization (WHO) recently declared the coronavirus outbreak a
global emergency as it spreads to countries outside of China and
the number of infected patients continues to grow.
Michael Favish, Guardion’s Chief Executive
Officer, commented, “We believe that this unique product can
provide a timely and effective immune response protocol to address
respiratory tract symptoms associated with global pandemics.”
About Guardion Health Sciences, Inc.
Guardion was formed as an ocular health sciences
company to develop, formulate, manufacture and distribute
condition-specific medical foods supported by evidence-based
protocols, with an initial medical food product, Lumega-Z, that
addresses a depleted macular protective pigment, a known risk
factor for age-related macular degeneration (“AMD”) and a
significant component of functional vision performance. Guardion
has also developed a proprietary medical device, the MapcatSF®,
which accurately measures the macular pigment density, therefore
providing the only two-pronged evidence-based protocol for the
treatment of a depleted macular protective pigment. Information and
risk factors with respect to Guardion and its business, including
its ability to successfully develop and commercialize its
proprietary products and technologies, may be obtained in the
Company’s filings with the SEC at www.sec.gov.
About VectorVision®
VectorVision® specializes in the standardization
of contrast sensitivity, glare sensitivity, low contrast acuity,
and ETDRS acuity vision testing. Its patented standardization
system provides the practitioner or researcher the ability to
delineate very small changes in visual capability, either as
compared to the population or from visit to visit. VectorVision®’s
CSV-1000 device is considered the standard of care for clinical
trials. VectorVision® is a wholly-owned subsidiary of Guardion.
Guardion has completed development of the
proprietary VectorVision® CSV-2000 standardized contrast
sensitivity test and recently introduced the commercial product to
the marketplace. The CSV-2000 is the only computer-generated vision
testing instrument available that will provide the optical
marketplace with the Company’s proprietary, industry-standard
contrast sensitivity test, along with a full suite of standard
vision testing protocols. The proprietary standardization
methodology incorporated into the CSV-2000 includes a patented
technology known as AcQviz that automatically and constantly
measures and adjusts screen luminance to a fixed standard light
level for vision testing.
About NutriGuard
NutriGuard formulates high-quality,
scientifically-credible nutraceuticals, which are designed to
supplement consumers’ diets and assist in the prevention and
management of an array of diseases and conditions. NutriGuard uses
pharmaceutical standards to establish the safety and efficacy of
the products it develops and markets, and also maintains that
commitment through rigorous manufacturing and quality assurance
programs. Guardion plans to increase NutriGuard’s existing customer
base and build on its product platform by making NutriGuard
products available to patients directly and through recommendations
by their physicians.
Forward-Looking Statement Disclaimer
With the exception of the historical information
contained in this news release, the matters described herein may
contain forward-looking statements within the meaning of Section
27A of the Securities Act of 1933, as amended, and Section 21E of
the Securities Exchange Act of 1934, as amended. Statements
preceded by, followed by or that otherwise include the words
“believes,” “expects,” “anticipates,” “intends,” “projects,”
“estimates,” “plans” and similar expressions or future or
conditional verbs such as “will,” “should,” “would,” “may” and
“could” are generally forward-looking in nature and not historical
facts, although not all forward-looking statements include the
foregoing. These statements involve unknown risks and uncertainties
that may individually or materially impact the matters discussed
herein for a variety of reasons that are outside the control of the
Company, including, but not limited to, the Company’s ability to
raise sufficient financing to implement its business plan and the
Company’s ability to successfully develop and commercialize its
proprietary products and technologies, including acuMMUNE. Readers
are cautioned not to place undue reliance on these forward-looking
statements, as actual results could differ materially from those
described in the forward-looking statements contained herein.
Readers are urged to read the risk factors set forth in the
Company’s filings with the SEC, which are available at the SEC’s
website (www.sec.gov). The Company disclaims any intention or
obligation to update or revise any forward-looking statements,
whether as a result of new information, future events or
otherwise.
Guardion Health Sciences, Inc. 15150 Avenue of Science, Ste. 200
San Diego, CA 92128Ph 858.605.9055; Fax
858.630.5543www.guardionhealth.com
Investor Relations Contact:
Porter, LeVay & Rose, Inc.Michael PorterTelephone: (212)
564-4700E-mail: mike@plrinvest.com
Matthew AbenanteTelephone: (212) 564-4700E-mail:
matthew@plrinvest.com
Guardion Health Sciences (NASDAQ:GHSI)
Historical Stock Chart
From Aug 2024 to Sep 2024
Guardion Health Sciences (NASDAQ:GHSI)
Historical Stock Chart
From Sep 2023 to Sep 2024